Study of antibiotics in people on heart-lung machine
Part of Heart & circulation, Infections clinical trials.
This study looks at how well certain strong antibiotics (Piperacillin-Tazobactam, Cefepime, or Meropenem) work in the body when a person is on a heart-lung machine called VA-ECMO. It aims to find the best dose for these antibiotics in this situation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently on a heart-lung machine called VA-ECMO
- You need to start a new antibiotic treatment with one of these drugs: Piperacillin-Tazobactam, Cefepime, or Meropenem
- You are expected to live longer than 24 hours
- You or a trusted person can give permission to join the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well antibiotics and other anti-infective drugs work in very sick patients who are on a heart-lung machine called ECMO. If you're in the ICU with a serious infection, this trial could help doctors figure out the best dose for you.
This trial tests if unloading the heart during ECMO support helps patients recover better from cardiogenic shock. It compares different ways to reduce the heart's workload.
This trial tests how a new antibiotic (meropenem-pralubactam) moves into the lungs of healthy people in China. You will receive the medicine through an IV, and a lung fluid sample will be collected to measure the drug levels.
This trial studies how to give the right dose of common antibiotics to children on ECMO (a heart-lung bypass machine). The goal is to help doctors choose the best dose to fight infections while keeping the child safe.
This trial tests whether adding an inhaled antibiotic (amikacin) to standard IV antibiotics can better treat a serious lung infection (pneumonia caused by Gram-negative bacteria) in patients on a heart-lung machine (ECMO) and a breathing tube. If you or your loved one is on ECMO and has this type of pneumonia, this study may offer a new treatment approach.
This trial studies how well certain new antibiotics work in patients with gram-negative bacterial infections who are receiving extracorporeal life support (like ECMO or dialysis) in the intensive care unit. It uses drug monitoring to make sure the right dose is given.
Hear when a new Cardiogenic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.